This trial was designed to evaluate safety parameters for glycopyrrolate over a six-month period.
Larry Dillaha, chief medical officer of Sciele Pharma, said: “We are excited to have completed this phase III safety trial for glycopyrrolate. With the timely completion of this trial, our next step will be to file a new drug application with the FDA, which we expect to do in the third quarter of 2008.”